BioNTech Earnings Preview: Q2 2025 Expectations

BioNTech (NASDAQ:BNTX) is set to announce Q2 earnings on August 4th. The consensus EPS estimate is -$1.65 (+50.9% Y/Y) and the revenue estimate is $309.71M (+140.6% Y/Y). Over the last year, BNTX has seen a significant increase in both EPS and revenue, driven by strong demand for its COVID-19 vaccine and other products.

BioNTech (NASDAQ: BNTX) is scheduled to announce its Q2 2025 earnings results on Monday, August 4th, before the market opens. The consensus EPS estimate is -$1.65, representing a 50.9% year-over-year (Y/Y) increase, while the consensus revenue estimate stands at $309.71 million, up 140.6% Y/Y. Over the past year, BNTX has consistently outperformed EPS estimates 75% of the time and revenue estimates 100% of the time. In the last three months, EPS estimates have seen 8 upward revisions and 1 downward, while revenue estimates have seen 5 upward revisions and 1 downward.

The strong performance can be attributed to the significant demand for BioNTech's COVID-19 vaccine and other products. The company's acquisition of CureVac has brought a complementary method to target cancer, further bolstering its portfolio. Additionally, the Bristol-Myers and BioNTech deal has been mutually beneficial, although one might be considered the better investment.

Investors and financial professionals are closely monitoring these earnings to gauge the company's performance and future prospects. The upcoming earnings report will provide valuable insights into BioNTech's financial health and strategic direction.

[1] https://seekingalpha.com/news/4476670-biontech-q2-2025-earnings-preview